With Juno deal, Celgene bets on the future of CAR-T — and its own – STAT
STAT |
With Juno deal, Celgene bets on the future of CAR–T — and its own
STAT y acquiring Juno Therapeutics (JUNO 1) for $9 billion, Celgene (CELG 2) is making a bullish bet on genetically engineered cells known as CAR-Ts becoming a cornerstone of cancer treatment. The same strategic reasoning compelled Gilead Sciences (GILD 3 … UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodes With $9 Billion Juno Deal, Celgene Doubles Down on Cancer Muscle CAR? Celgene's $9B offer for Juno starts pundits weighing traction |
